INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 159 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2017. The put-call ratio across all filers is 0.64 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2020 | $1,139,000 | -62.3% | 18,100 | -25.8% | 0.60% | +70.9% |
Q4 2019 | $3,023,000 | -34.6% | 24,400 | -65.0% | 0.35% | -40.1% |
Q3 2019 | $4,625,000 | -16.6% | 69,700 | 0.0% | 0.59% | +53.9% |
Q2 2019 | $5,546,000 | -47.7% | 69,700 | -26.5% | 0.38% | -21.8% |
Q1 2019 | $10,604,000 | +100.9% | 94,800 | +50.7% | 0.49% | +58.9% |
Q2 2018 | $5,277,000 | -37.2% | 62,900 | -53.9% | 0.31% | -42.4% |
Q1 2018 | $8,397,000 | -20.6% | 136,500 | -24.6% | 0.54% | -5.5% |
Q4 2017 | $10,580,000 | +44.8% | 181,110 | +43.9% | 0.57% | +44.6% |
Q3 2017 | $7,307,000 | +3430.0% | 125,900 | +4096.7% | 0.39% | +734.0% |
Q3 2013 | $207,000 | – | 3,000 | – | 0.05% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Carmignac Gestion | 2,028,192 | $229,389,000 | 1.76% |
Orbimed Advisors | 1,037,000 | $117,285,000 | 1.33% |
BB BIOTECH AG | 255,719 | $28,922,000 | 0.95% |
ALTRINSIC GLOBAL ADVISORS LLC | 193,369 | $21,870,000 | 0.74% |
FALCON POINT CAPITAL, LLC | 44,573 | $5,041,000 | 0.67% |
Rhenman & Partners Asset Management AB | 30,000 | $3,393,000 | 0.54% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 11,155 | $1,262,000 | 0.48% |
NATIONAL PLANNING CORP | 52,400 | $5,888,000 | 0.44% |
HIGHFIELDS CAPITAL MANAGEMENT LP | 364,232 | $41,195,000 | 0.38% |
SPHERA FUNDS MANAGEMENT LTD. | 15,000 | $1,697,000 | 0.33% |